Skip to main content
Fig. 4 | Porcine Health Management

Fig. 4

From: Field evaluation of the safety and compatibility of a combined vaccine against porcine parvovirus 1 and porcine reproductive and respiratory syndrome virus in breeding animals

Fig. 4

Proportion (±CI 95%) of seropositive animals against PPV1 per group, from phase I (a) and phase II (b) of experiment B. In phase I (a), primary vaccination (SD 0) with ReproCyc® ParvoFLEX alone (group BI-PPV1) or in combination with ReproCyc® PRRS EU (group BI- PRRSV+PPV1) and boost vaccination with ReproCyc® ParvoFLEX alone 3 weeks apart (SD 21). In phase II (b), re-vaccination (SD 201) with ReproCyc® ParvoFLEX alone (group BII-PPV1) or mixed with ReproCyc® PRRS EU (group BII- PRRSV+PPV1). Values of Fisher’s exact test for comparison between groups reveled no statistically significant differences at any time point

Back to article page

Porcine Health Management

ISSN: 2055-5660

Contact us